Article
Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic
spectrum of the R141H/F119L genotype
S Kjaergaard, M Schwartz, F Skovby
Department of
Clinical Genetics, University Hospital, Rigshospitalet 4062, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
Correspondence to: Dr Kjaergaard Susanne{at}rh.dk
Accepted 2 May 2001
AIMS
To delineate common and
variable features and outcome of children with congenital disorder of
glycosylation type Ia (CDG-Ia) caused by the frequent R141H/F119L
PMM2 genotype.
METHODS
Clinical data on 25 patients (mean age 7.6 years, range 0-19) were analysed.
RESULTS
All patients had an early
presentation with severe feeding problems and failure to thrive,
hypotonia, hepatic dysfunction, inverted nipples, and abnormal
subcutaneous fat pads. Eighteen patients were hospitalised in the
neonatal period. Developmental delay was obvious before age 6 months.
During the first seven months mean standard deviation score (SDS) for
weight and length decreased 2.7 (SD = 2) and 2.4 (SD = 2),
respectively. Mental retardation, ataxia, muscular atrophy, and febrile
seizures were consistent features after infancy. Variable features
included pericardial effusions, afebrile seizures, and stroke like
episodes. Computed tomography/magnetic resonance imaging of the brain
was normal in two patients examined before 4 months of age, but 18 children examined after 3 months of age had cerebellar atrophy, and 10 children also had supratentorial atrophy. Subsequent imaging showed
progression of the cerebellar and supratentorial atrophy in eight and
four of 10 children, respectively. Mean head circumference SDS declined
from zero to
1.9 SD from age 3 months to 5 years. Motor ability
ranged from none to walking with a rolator, and vocabulary ranged from
none to comprehensible speech. The overall mortality ascribed to CDG-Ia
was 18%.
CONCLUSION
Patients with the
R141H/F119L genotype have an early uniform presentation including
severe failure to thrive, but their functional outcome is variable.
This genotype may well cause clinical manifestations in the severe end
of the spectrum of CDG-Ia.
Keywords: congenital disorder of glycosylation type Ia; phenotype; phosphomannomutase deficiency
© 2001 by Archives of Disease in Childhood
This article has been cited by other articles:
-
van de Kamp, J M, Lefeber, D J, Ruijter, G J G, Steggerda, S J, den Hollander, N S, Willems, S M, Matthijs, G, Poorthuis, B J H M, Wevers, R A
(2007). Congenital disorder of glycosylation type Ia presenting with hydrops fetalis. J. Med. Genet.
44: 277-280
[Abstract] [Full Text] -
Kjaergaard, S, Muller, J, Skovby, F
(2002). Prepubertal growth in congenital disorder of glycosylation type Ia (CDG-Ia). Arch. Dis. Child.
87: 324-327
[Abstract] [Full Text] -
Westphal, V., Kjaergaard, S., Schollen, E., Martens, K., Grunewald, S., Schwartz, M., Matthijs, G., Freeze, H. H.
(2002). A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency. Hum Mol Genet
11: 599-604
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



